The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This is a pilot, multinational, randomized, double-blind, placebo-controlled safety and
efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart
failure with persistent hypotension and heart rate 75 to 150 beats/minute.